Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIF-MS phase 2 trial of ifenprodil in multiple sclerosis
2023-507874-42-00Phase 2Suspended
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ifenprodil in multiple sclerosis (MS), sponsored by Assistance publique - Hôpitaux de Paris. Started Aug 2024; status: suspended.
02
Drugs
ifenprodil
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-507874-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507874-42-00.